Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Larré is active.

Publication


Featured researches published by S. Larré.


Urologic Oncology-seminars and Original Investigations | 2017

Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes

Pierre Bigot; Jean-Christophe Bernhard; Vincent Flamand; Inderbir S. Gill; G. Verhoest; Jean Baptiste Beauval; François Xavier Nouhaud; Evren Süer; G. Ploussard; Jean François Hetet; J. Rigaud; Eduard Baco; S. Larré; Philippe Sebe; Nicolas Koutlidis; Aurélien Descazeaud; Masatoshi Eto; Arnaud Doerfler; Morgan Rouprêt; Nam Son Vuong; B. Reix; Toru Matsugasumi; Adnan El Bakri; Laurence Albiges; Michel Soulie; Jean-Jacques Patard; Arnaud Mejean; Karim Bensalah

OBJECTIVE To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). MATERIAL AND METHODS We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed. RESULTS We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. CONCLUSION Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.


The Journal of Sexual Medicine | 2013

Successful Medical Treatment of Glans Ischemia after Voluntary Buprenorphine Injection

François Brecheteau; Pierre Grison; Pierre Abraham; Souhil Lebdai; Steve Kemgang; Vincent Souday; Cosmina Nedelcu; Thibaut Culty; S. Larré; Abdel Rahmène Azzouzi; Pierre Bigot

INTRODUCTION The diverted use of synthetic opioid buprenorphine by drug addicts can be responsible for serious ischemic and infectious complications, particularly in the case of intravenous injection. AIM We present a case of serious glans ischemia after buprenorphine injection directly into the deep dorsal vein of the penis. Analysis using new medical imaging techniques and treatments is detailed below. METHODS A 26-year-old male drug addict presented with glans pain 4 days after self-injection of buprenorphine into the deep dorsal vein of the penis. The patient was apyretic and presented a urethral discharge. His glans was blue without discoloration on digital pressure. Additionally, his biologic and serologic tests were normal while bacteriology showed the presence of Enterobacter cloacae urethritis. RESULTS After 48 hours of intravenous antibiotic treatment without improvement, a specific medical treatment using enoxaparin and ilomedin was initiated, with the assumption that there was an ischemic complication. Laser speckle contrast imaging allowed confirmation of the presence of distal penis ischemia and provided an accurate mapping of the ischemic zone. A 28-day treatment combining antibiotics, subcutaneous heparin at curative dose, antiplatelet drug, ilomedin, and hyperbaric oxygen therapy resulted in clinical improvement of the lesions with no functional complications. CONCLUSIONS To date, no consensus exists on the proper diagnostic and treatment approach to severe glans ischemia due to buprenorphine injection into the deep dorsal vein of the penis. The results of laser speckle contrast imaging were of real interest during the process of diagnosis. In addition, the combination of ilomedin with hyperbaric oxygen therapy and anticoagulant and antiplatelet drugs appeared to be an effective therapy.


Progres En Urologie | 2018

Recommandations françaises du Comité de Cancérologie de l’AFU – actualisation 2018–2020 : tumeur de la surrénale

Morgan Rouprêt; Y. Neuzillet; G. Pignot; Eva Comperat; F. Audenet; Nadine Houede; S. Larré; A. Masson-Lecomte; P. Colin; S. Brunelle; Evanguelos Xylinas; Mathieu Roumiguié; Arnaud Mejean

OBJECTIVE: To propose updated French guidelines for non-muscle invasive (NMIBC) and muscle-invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2015 and 2018, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumor. The use of fluorescence and a second-look indication are essential to improve initial diagnosis. Risks of both recurrence and progression can be estimated using the EORTC score. A stratification of patients into low, intermediate and high risk groups is pivotal for recommending adjuvant treatment: instillation of chemotherapy (immediate post-operative, standard schedule) or intravesical BCG (standard schedule and maintenance). Cystectomy is recommended in BCG-refractory patients. Extension evaluation of MIBC is based on contrast-enhanced pelvic-abdominal and thoracic CT-scan. Multiparametric MRI can be an alternative. Cystectomy associated with extended lymph nodes dissection is considered the gold standard for non-metastatic MIBC. It should be preceded by cisplatin-based neoadjuvant chemotherapy in eligible patients. An orthotopic bladder substitution should be proposed to both male and female patients with no contraindication and in cases of negative frozen urethral samples; otherwise transileal ureterostomy is recommended as urinary diversion. All patients should be included in an Early Recovery After Surgery (ERAS) protocol. For metastatic MIBC, first-line chemotherapy using platin is recommended (GC or MVAC), when performans status (PS 60 mL/min) allow it (only in 50% of cases). In second line treatment, immunotherapy with pembrolizumab demonstrated a significant improvement in overall survival. CONCLUSION: These updated French guidelines will contribute to increase the level of urological care for the diagnosis and treatment for NMIBC and MIBC.


World Journal of Urology | 2016

The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery

Pierre Bigot; Jean Christophe Bernhard; Inderbir S. Gill; Nam Son Vuong; G. Verhoest; Vincent Flamand; B. Reix; Evren Süer; İlker Gökçe; Jean Baptiste Beauval; François Xavier Nouhaud; Masatoshi Eto; Eduard Baco; Toru Matsugasumi; Yvonne Chowaniec; J. Rigaud; C. Lenormand; C. Pfister; Jean François Hetet; G. Ploussard; Morgan Rouprêt; Priscilla Léon; Adnan El Bakri; S. Larré; Xavier Tillou; Arnaud Doerfler; Aurélien Descazeaud; Nicolas Koutlidis; A. Schneider; Philippe Sebe


Progres En Urologie | 2015

Surveillance des carcinomes urothéliaux : revue du Comité de cancérologie de l’Association française d’urologie

P. Colin; Y. Neuzillet; G. Pignot; Morgan Rouprêt; E. Comperat; S. Larré; Catherine Roy; H. Quintens; N. Houédé; M. Soulié; Christian Pfister


Progres En Urologie | 2016

Données comparatives moléculaires, précliniques et cliniques des différentes souches de bacille de Calmette-Guérin (BCG) : revue de la littérature du Comité de cancérologie de l’Association française d’urologie (CCAFU)

Y. Neuzillet; F. Dubosq; Evanguelos Xylinas; P. Colin; Eva Comperat; Nadine Houede; S. Larré; Alexandra Masson-Lecomte; G. Pignot; P. Puech; Mathieu Roumiguié; Arnaud Mejean; Morgan Rouprêt


European Urology Supplements | 2015

727 From clinically localized to pT3a renal cell carcinoma: What are the predictive factors of unexpected pathologic upstaging?

J-C. Bernhard; J.J. Patard; Pierre Bigot; Evren Süer; N. Vuong; G. Verhoest; Q. Alimi; Vincent Flamand; B. Reix; J-B. Beauval; T. Benoit; F. Nouhaud; C. Lenormand; N. Hamidi; A. Hung; J. Cai; Masatoshi Eto; S. Larré; A. El Bakri; Eduard Baco; G. Ploussard; Nicolas Koutlidis; A. Schneider; Morgan Rouprêt; Priscilla Léon; J. Carrouget; S. Droupy; S. Marchal; Arnaud Doerfler; S. Seddik


Progres En Urologie | 2018

Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : tumeurs de la voie excrétrice supérieure

Morgan Rouprêt; Evanguelos Xylinas; P. Colin; Nadine Houede; Eva Comperat; F. Audenet; S. Larré; A. Masson-Lecomte; G. Pignot; S. Brunelle; Mathieu Roumiguié; Y. Neuzillet; Arnaud Mejean


Progres En Urologie | 2017

Impact de la pénurie de BCG endovésical sur le nombre de cystectomies et résections réalisées en France

S. Larré; H. Bensadoun; Y. Neuzillet; P. Colin; E. Compera; F. Dubosq; Nadine Houede; P. Puech; Mathieu Roumiguié; Evanguelos Xylinas; Arnaud Mejean; Morgan Rouprêt


Progres En Urologie | 2016

Twitter émerge comme une source d’information incontournable en oncologie urologique et en recherche biomédicale

A. El bakri; E. Habran; S. Larré

Collaboration


Dive into the S. Larré's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Ploussard

Saint Louis University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eduard Baco

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Inderbir S. Gill

University of Southern California

View shared research outputs
Researchain Logo
Decentralizing Knowledge